Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Artiva Biotherapeutics, Inc.ARTV · Entity 5404 | Director | September 10, 2026 | September 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Artiva Biotherapeutics, Inc.
Report date September 10, 2026 · Filed September 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.42 · Expires 2036-09-09 | Direct | 16,250 |
Reported balance
After 2026-09-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-10 · Grant · Acquired 16,250 · Balance 16,250 F1: The shares subject to the option will vest in full on the earlier of September 10, 2027, or the date of the Issuer's 2027 annual stockholder meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest in full on the earlier of September 10, 2027, or the date of the Issuer's 2027 annual stockholder meeting.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BRISTOL MYERS SQUIBB CO
Report date July 01, 2014 · Filed July 02, 2014
Section 16 reporting ended · disclosed 2014-07-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.10 par valueSEC Table I · non-derivative | Direct | 94,374.041 |
Ending reported balance
After 2014-07-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2014-07-01 · Exercise / conversion · Acquired 4,671 · Balance 96,477.041 Row 2 · 2014-07-01 · Tax withholding · Disposed 2,103 · Balance 94,374.041 F1: Shares withheld for payment of taxes upon vesting of restricted stock units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 9,340 |
Reported balance
After 2014-07-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2014-07-01 · Exercise / conversion · Disposed 4,671 · Balance 9,340 F2: Each restricted stock unit converts into one share of common stock upon vesting. F3: Represents vesting of one-third of restricted stock units granted on July 1, 2011. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld for payment of taxes upon vesting of restricted stock units.
F2: Each restricted stock unit converts into one share of common stock upon vesting.
F3: Represents vesting of one-third of restricted stock units granted on July 1, 2011.
Cabaletta Bio, Inc.
Report date June 01, 2021 · Filed June 28, 2021 · Amendment
Section 16 reporting ended · disclosed 2021-06-28. Current position is not established by this disclosure.
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.00 · Expires 2031-05-31 | Direct | 0 |
Reported balance
After 2021-06-01 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2021-06-01 · Grant · Disposed 22,000 · Balance 0 F1: This option shall vest in accordance with the following schedule: (1) 25% of the shares subject to the option shall vest on June 24, 2022 and (2) the remaining 75% of the shares subject to the option shall vest in equal quarterly installments over the next 3 years, subject to the Reporting Person's continued service relationship with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest in accordance with the following schedule: (1) 25% of the shares subject to the option shall vest on June 24, 2022 and (2) the remaining 75% of the shares subject to the option shall vest in equal quarterly installments over the next 3 years, subject to the Reporting Person's continued service relationship with the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 10, 2026 Filed Sep 14, 2026 20:03 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | GrantDirector Stock Option (Right to Buy) · Derivative | 16,250 | $0.00 Strike: $10.42 | $0.00 |
DisclosureSEC source: 0001193125-26-390531 · ownership.xml · derivative · entry 1 DANIELS BRIAN · CIK 0001428698 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,250 Underlying: Common Stock · 16,250 shares Expires 2036-09-09 F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of September 10, 2027, or the date of the Issuer's 2027 annual stockholder meeting. Read SEC document |
| September 08, 2026 Filed Sep 8, 2026 21:56 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | GrantDirector Stock Option (Right to Buy) · Derivative | 13,750 | $0.00 Strike: $10.88 | $0.00 |
DisclosureSEC source: 0001193125-26-385414 · ownership.xml · derivative · entry 1 DANIELS BRIAN · CIK 0001428698 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,750 Underlying: Common Stock · 13,750 shares Expires 2036-09-07 F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of September 8, 2027, or the date of the Issuer's 2027 annual stockholder meeting. Read SEC document |
| June 24, 2025 Filed Jun 26, 2025 20:30 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | GrantDirector Stock Option (Right to Buy) · Derivative | 13,750 | $0.00 Strike: $1.61 | $0.00 |
DisclosureSEC source: 0001415889-25-018275 · form4-06262025_040601.xml · derivative · entry 1 DANIELS BRIAN · CIK 0001428698 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,750 Underlying: Common Stock · 13,750 shares Expires 2035-06-23 F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of June 24, 2026, or the date of the Issuer's 2026 annual stockholder meeting. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 20:30 UTC | Cabaletta Bio, Inc. CABA · Entity 5418 | GrantStock Option (Right to buy) · Derivative | 22,000 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0000899243-21-021791 · doc4.xml · derivative · entry 1 DANIELS BRIAN · CIK 0001428698 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2031-05-31 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (1) June 1, 2022 or (2) the date of the next annual meeting of the Corporation's stockholders. Read SEC document |
| June 01, 2021 Filed Jun 28, 2021 20:30 UTC Amendment | Cabaletta Bio, Inc. CABA · Entity 5418 | GrantStock Option (Right to buy) · Derivative | 22,000 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0000899243-21-026199 · doc4a.xml · derivative · entry 1 DANIELS BRIAN · CIK 0001428698 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,000 shares Expires 2031-05-31 F1 · derivative.exercise_date: This option shall vest in accordance with the following schedule: (1) 25% of the shares subject to the option shall vest on June 24, 2022 and (2) the remaining 75% of the shares subject to the option shall vest in equal quarterly installments over the next 3 years, subject to the Reporting Person's continued service relationship with the Issuer. Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 22:47 UTC | Cabaletta Bio, Inc. CABA · Entity 5418 | GrantStock Option (Right to Buy) · Derivative | 44,000 | $0.00 Strike: $15.42 | $0.00 |
DisclosureSEC source: 0000899243-20-004509 · doc4.xml · derivative · entry 1 DANIELS BRIAN · CIK 0001428698 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2030-02-10 F1 · derivative.exercise_date: The Shares shall vest and become exercisable in 12 equal quarterly installments commencing on October 25, 2019, provided that the Reporting Person continues to have a Service Relationship with the Company on each vesting date. Read SEC document |
| July 01, 2014 Filed Jul 2, 2014 22:35 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionRestricted Stock Units · Derivative | 4,671 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-14-000203 · wf-form4_140434052492921.xml · derivative · entry 3 DANIELS BRIAN · CIK 0001428698 · SVP Global Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,340 Underlying: Common Stock, $0.10 par value · 4,671 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F3 · derivative.exercise_date: Represents vesting of one-third of restricted stock units granted on July 1, 2011. F3 · derivative.expiration_date: Represents vesting of one-third of restricted stock units granted on July 1, 2011. Read SEC document |
| July 01, 2014 Filed Jul 2, 2014 22:35 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 2,103 | $48.12 | $101,196.36 |
DisclosureSEC source: 0000014272-14-000203 · wf-form4_140434052492921.xml · nonDerivative · entry 2 DANIELS BRIAN · CIK 0001428698 · SVP Global Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,374.041 F1 · shares: Shares withheld for payment of taxes upon vesting of restricted stock units. Read SEC document |
| July 01, 2014 Filed Jul 2, 2014 22:35 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 4,671 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-14-000203 · wf-form4_140434052492921.xml · nonDerivative · entry 1 DANIELS BRIAN · CIK 0001428698 · SVP Global Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,477.041 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2014 Filed Mar 12, 2014 20:51 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantMarket Share Units · Derivative | 6,741 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-14-000140 · wf-form4_139465750302579.xml · derivative · entry 5 DANIELS BRIAN · CIK 0001428698 · SVP Global Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,741 Underlying: Common Stock, $0.10 par value · 6,741 shares Expires 2018-03-10 F4 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F5 · derivative.exercise_date: Twenty-five percent of the market share unit award will vest on each of the first, second, third and fourth anniversaries of the grant date. F5 · derivative.expiration_date: Twenty-five percent of the market share unit award will vest on each of the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| March 10, 2014 Filed Mar 12, 2014 20:51 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionMarket Share Units · Derivative | 2,528 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-14-000140 · wf-form4_139465750302579.xml · derivative · entry 4 DANIELS BRIAN · CIK 0001428698 · SVP Global Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,587 Underlying: Common Stock, $0.10 par value · 2,528 shares Expires 2017-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F1 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 10, 2013. F1 · derivative.expiration_date: Represents vesting of one-quarter of market share units granted on March 10, 2013. Read SEC document |
| March 10, 2014 Filed Mar 12, 2014 20:51 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 1,655 | $56.14 | $92,911.70 |
DisclosureSEC source: 0000014272-14-000140 · wf-form4_139465750302579.xml · nonDerivative · entry 3 DANIELS BRIAN · CIK 0001428698 · SVP Global Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,806.041 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| March 10, 2014 Filed Mar 12, 2014 20:51 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 1,147 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-14-000140 · wf-form4_139465750302579.xml · nonDerivative · entry 2 DANIELS BRIAN · CIK 0001428698 · SVP Global Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,461.041 F2 · shares: Adjustment reflects additional shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| March 10, 2014 Filed Mar 12, 2014 20:51 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 2,528 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-14-000140 · wf-form4_139465750302579.xml · nonDerivative · entry 1 DANIELS BRIAN · CIK 0001428698 · SVP Global Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,314.041 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents vesting of one-quarter of market share units granted on March 10, 2013. Read SEC document |
| March 06, 2014 Filed Mar 10, 2014 20:41 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionMarket Share Units · Derivative | 3,010 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-14-000114 · wf-form4_139448409055140.xml · derivative · entry 4 DANIELS BRIAN · CIK 0001428698 · SVP Global Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,019 Underlying: Common Stock, $0.10 par value · 3,010 shares Expires 2016-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F1 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 6, 2012. F1 · derivative.expiration_date: Represents vesting of one-quarter of market share units granted on March 6, 2012. Read SEC document |
| March 06, 2014 Filed Mar 10, 2014 20:41 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 2,276 | $55.56 | $126,454.56 |
DisclosureSEC source: 0000014272-14-000114 · wf-form4_139448409055140.xml · nonDerivative · entry 3 DANIELS BRIAN · CIK 0001428698 · SVP Global Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,786.041 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| March 06, 2014 Filed Mar 10, 2014 20:41 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 2,044 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-14-000114 · wf-form4_139448409055140.xml · nonDerivative · entry 2 DANIELS BRIAN · CIK 0001428698 · SVP Global Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,062.041 F2 · shares: Adjustment reflects additional shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| March 06, 2014 Filed Mar 10, 2014 20:41 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 3,010 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-14-000114 · wf-form4_139448409055140.xml · nonDerivative · entry 1 DANIELS BRIAN · CIK 0001428698 · SVP Global Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,018.041 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents vesting of one-quarter of market share units granted on March 6, 2012. Read SEC document |
| March 03, 2014 Filed Mar 5, 2014 21:37 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherPerformance Shares · Derivative | 160.1904 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-14-000087 · wf-form4_139405541394476.xml · derivative · entry 20 DANIELS BRIAN · CIK 0001428698 · SVP Global Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,295.1904 Underlying: Common Stock, $0.10 par value · 160.1904 shares Expires 2016-03-31 F19 · derivative.exercise_price: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2016. F20 · shares: Represents dividend equivalents earned under the 2013-2015 Long-Term Performance Award. F19 · derivative.exercise_date: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2016. F19 · derivative.expiration_date: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2016. Read SEC document |
| March 03, 2014 Filed Mar 5, 2014 21:37 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantPerformance Shares · Derivative | 5,135 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-14-000087 · wf-form4_139405541394476.xml · derivative · entry 19 DANIELS BRIAN · CIK 0001428698 · SVP Global Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,135 Underlying: Common Stock, $0.10 par value · 5,135 shares Expires 2016-03-31 F17 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2016. F18 · shares: Represents performance shares earned under the 2013-2015 Long-Term Performance Award. F17 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2016. F17 · derivative.expiration_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2016. Read SEC document |
| March 03, 2014 Filed Mar 5, 2014 21:37 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherPerformance Shares · Derivative | 425.4115 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-14-000087 · wf-form4_139405541394476.xml · derivative · entry 18 DANIELS BRIAN · CIK 0001428698 · SVP Global Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,062.2385 Underlying: Common Stock, $0.10 par value · 425.4115 shares Expires 2015-03-31 F15 · derivative.exercise_price: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2015. F16 · shares: Represents dividend equivalents earned under the 2012-2014 Long-Term Performance Award. F15 · derivative.exercise_date: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2015. F15 · derivative.expiration_date: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2015. Read SEC document |
| March 03, 2014 Filed Mar 5, 2014 21:37 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantPerformance Shares · Derivative | 6,112 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-14-000087 · wf-form4_139405541394476.xml · derivative · entry 17 DANIELS BRIAN · CIK 0001428698 · SVP Global Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,636.827 Underlying: Common Stock, $0.10 par value · 6,112 shares Expires 2015-03-31 F13 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2015. F14 · shares: Represents performance shares earned under the 2012-2014 Long-Term Performance Award. F13 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2015. F13 · derivative.expiration_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2015. Read SEC document |
| March 03, 2014 Filed Mar 5, 2014 21:37 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionPerformance Shares · Derivative | 40,119 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-14-000087 · wf-form4_139405541394476.xml · derivative · entry 16 DANIELS BRIAN · CIK 0001428698 · SVP Global Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 40,119 shares Expires 2014-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2014. F6 · shares: Represents distribution of performance shares earned under the 2011-2013 Long-Term Performance Award. F9 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2014. F9 · derivative.expiration_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2014. Read SEC document |
| March 03, 2014 Filed Mar 5, 2014 21:37 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherPerformance Shares · Derivative | 1,212.5733 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-14-000087 · wf-form4_139405541394476.xml · derivative · entry 15 DANIELS BRIAN · CIK 0001428698 · SVP Global Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,119 Underlying: Common Stock, $0.10 par value · 1,212.5733 shares Expires 2014-03-31 F11 · derivative.exercise_price: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2014. F12 · shares: Represents dividend equivalents earned under the 2011-2013 Long-Term Performance Award. F11 · derivative.exercise_date: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2014. F11 · derivative.expiration_date: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2014. Read SEC document |
| March 03, 2014 Filed Mar 5, 2014 21:37 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantPerformance Shares · Derivative | 18,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-14-000087 · wf-form4_139405541394476.xml · derivative · entry 14 DANIELS BRIAN · CIK 0001428698 · SVP Global Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,906.4267 Underlying: Common Stock, $0.10 par value · 18,600 shares Expires 2014-03-31 F9 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2014. F10 · shares: Represents performance shares earned under the 2011-2013 Long-Term Performance Award. F9 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2014. F9 · derivative.expiration_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2014. Read SEC document |
| March 03, 2014 Filed Mar 5, 2014 21:37 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionMarket Share Units · Derivative | 3,703 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-14-000087 · wf-form4_139405541394476.xml · derivative · entry 13 DANIELS BRIAN · CIK 0001428698 · SVP Global Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,703 Underlying: Common Stock, $0.10 par value · 3,703 shares Expires 2015-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F5 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 1, 2011. F5 · derivative.expiration_date: Represents vesting of one-quarter of market share units granted on March 1, 2011. Read SEC document |
| March 03, 2014 Filed Mar 5, 2014 21:37 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionMarket Share Units · Derivative | 3,813 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-14-000087 · wf-form4_139405541394476.xml · derivative · entry 12 DANIELS BRIAN · CIK 0001428698 · SVP Global Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 3,813 shares Expires 2014-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F3 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 2, 2010. F3 · derivative.expiration_date: Represents vesting of one-quarter of market share units granted on March 2, 2010. Read SEC document |
| March 03, 2014 Filed Mar 5, 2014 21:37 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionRestricted Stock Units · Derivative | 2,691 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-14-000087 · wf-form4_139405541394476.xml · derivative · entry 11 DANIELS BRIAN · CIK 0001428698 · SVP Global Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 2,691 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F1 · derivative.exercise_date: Represents vesting of one-third of restricted stock units granted on March 3, 2009. F1 · derivative.expiration_date: Represents vesting of one-third of restricted stock units granted on March 3, 2009. Read SEC document |
| March 03, 2014 Filed Mar 5, 2014 21:37 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 16,402 | $53.49 | $877,342.98 |
DisclosureSEC source: 0000014272-14-000087 · wf-form4_139405541394476.xml · nonDerivative · entry 10 DANIELS BRIAN · CIK 0001428698 · SVP Global Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,008.041 F2 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| March 03, 2014 Filed Mar 5, 2014 21:37 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 40,119 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-14-000087 · wf-form4_139405541394476.xml · nonDerivative · entry 9 DANIELS BRIAN · CIK 0001428698 · SVP Global Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,410.041 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · shares: Represents distribution of performance shares earned under the 2011-2013 Long-Term Performance Award. Read SEC document |
| March 03, 2014 Filed Mar 5, 2014 21:37 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 3,335 | $53.49 | $178,389.15 |
DisclosureSEC source: 0000014272-14-000087 · wf-form4_139405541394476.xml · nonDerivative · entry 8 DANIELS BRIAN · CIK 0001428698 · SVP Global Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,291.041 F2 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| March 03, 2014 Filed Mar 5, 2014 21:37 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 3,703 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-14-000087 · wf-form4_139405541394476.xml · nonDerivative · entry 7 DANIELS BRIAN · CIK 0001428698 · SVP Global Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,626.041 F4 · shares: Adjustment reflects additional shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| March 03, 2014 Filed Mar 5, 2014 21:37 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 3,703 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-14-000087 · wf-form4_139405541394476.xml · nonDerivative · entry 6 DANIELS BRIAN · CIK 0001428698 · SVP Global Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,923.041 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: Represents vesting of one-quarter of market share units granted on March 1, 2011. Read SEC document |
| March 03, 2014 Filed Mar 5, 2014 21:37 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 3,434 | $53.49 | $183,684.66 |
DisclosureSEC source: 0000014272-14-000087 · wf-form4_139405541394476.xml · nonDerivative · entry 5 DANIELS BRIAN · CIK 0001428698 · SVP Global Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,220.041 F2 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| March 03, 2014 Filed Mar 5, 2014 21:37 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 3,813 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-14-000087 · wf-form4_139405541394476.xml · nonDerivative · entry 4 DANIELS BRIAN · CIK 0001428698 · SVP Global Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,654.041 F4 · shares: Adjustment reflects additional shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| March 03, 2014 Filed Mar 5, 2014 21:37 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 3,813 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-14-000087 · wf-form4_139405541394476.xml · nonDerivative · entry 3 DANIELS BRIAN · CIK 0001428698 · SVP Global Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,841.041 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Represents vesting of one-quarter of market share units granted on March 2, 2010. Read SEC document |
| March 03, 2014 Filed Mar 5, 2014 21:37 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 1,212 | $53.49 | $64,829.88 |
DisclosureSEC source: 0000014272-14-000087 · wf-form4_139405541394476.xml · nonDerivative · entry 2 DANIELS BRIAN · CIK 0001428698 · SVP Global Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,028.041 F2 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| March 03, 2014 Filed Mar 5, 2014 21:37 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 2,691 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-14-000087 · wf-form4_139405541394476.xml · nonDerivative · entry 1 DANIELS BRIAN · CIK 0001428698 · SVP Global Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,240.041 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents vesting of one-third of restricted stock units granted on March 3, 2009. Read SEC document |
| February 06, 2014 Filed Feb 6, 2014 22:29 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionOption (right to buy) · Derivative | 18,750 | $0.00 Strike: $28.11 | $0.00 |
DisclosureSEC source: 0000014272-14-000049 · wf-form4_139172573779356.xml · derivative · entry 3 DANIELS BRIAN · CIK 0001428698 · SVP Global Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 18,750 shares Expires 2014-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Twenty-five percent of the stock option award vested on each of the first, second, third, and fourth anniversaries of the grant date, which was March 2, 2004. Read SEC document |
| February 06, 2014 Filed Feb 6, 2014 22:29 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | SaleCommon Stock, $0.10 par value | 28,440 | $48.93 | $1,391,432.69 |
DisclosureSEC source: 0000014272-14-000049 · wf-form4_139172573779356.xml · nonDerivative · entry 2 DANIELS BRIAN · CIK 0001428698 · SVP Global Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,549.041 F1 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $48.87 to $48.97, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 06, 2014 Filed Feb 6, 2014 22:29 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 18,750 | $28.11 | $527,062.50 |
DisclosureSEC source: 0000014272-14-000049 · wf-form4_139172573779356.xml · nonDerivative · entry 1 DANIELS BRIAN · CIK 0001428698 · SVP Global Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,989.041 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 08, 2013 Filed May 8, 2013 20:25 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | SaleCommon Stock, $0.10 par value | 15,000 | $39.93 | $598,950.00 |
DisclosureSEC source: 0001225208-13-011656 · doc4.xml · nonDerivative · entry 1 DANIELS BRIAN · CIK 0001428698 · SVP Global Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,239.041 F1 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $39.90 to $39.99, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 10, 2013 Filed Mar 11, 2013 21:08 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantMarket Share Units · Derivative | 10,115 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007260 · doc4.xml · derivative · entry 1 DANIELS BRIAN · CIK 0001428698 · SVP Global Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,115 Underlying: Common Stock, $0.10 par value · 10,115 shares Expires 2017-03-10 F1 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F2 · derivative.exercise_date: Twenty-five percent of the market share unit award will vest on each of the first, second, third and fourth anniversaries of the grant date. F2 · derivative.expiration_date: Twenty-five percent of the market share unit award will vest on each of the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:43 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherPerformance Shares · Derivative | 288.827 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007232 · doc4.xml · derivative · entry 21 DANIELS BRIAN · CIK 0001428698 · SVP Global Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,524.827 Underlying: Common Stock, $0.10 par value · 288.827 shares Expires 2015-03-31 F20 · derivative.exercise_price: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2015. F21 · shares: Represents dividend equivalents earned under the 2012-2014 Long-Term Performance Award. F20 · derivative.exercise_date: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2015. F20 · derivative.expiration_date: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2015. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:43 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantPerformance Shares · Derivative | 7,236 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007232 · doc4.xml · derivative · entry 20 DANIELS BRIAN · CIK 0001428698 · SVP Global Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,236 Underlying: Common Stock, $0.10 par value · 7,236 shares Expires 2015-03-31 F18 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2015. F19 · shares: Represents performance shares earned under the 2012-2014 Long-Term Performance Award. F18 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2015. F18 · derivative.expiration_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2015. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:43 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherPerformance Shares · Derivative | 779.4267 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007232 · doc4.xml · derivative · entry 19 DANIELS BRIAN · CIK 0001428698 · SVP Global Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,306.4267 Underlying: Common Stock, $0.10 par value · 779.4267 shares Expires 2014-03-31 F16 · derivative.exercise_price: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2014. F17 · shares: Represents dividend equivalents earned under the 2011-2013 Long-Term Performance Award. F16 · derivative.exercise_date: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2014. F16 · derivative.expiration_date: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2014. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:43 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantPerformance Shares · Derivative | 8,808 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007232 · doc4.xml · derivative · entry 18 DANIELS BRIAN · CIK 0001428698 · SVP Global Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,527 Underlying: Common Stock, $0.10 par value · 8,808 shares Expires 2014-03-31 F14 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2014. F15 · shares: Represents performance shares earned under the 2011-2013 Long-Term Performance Award. F14 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2014. F14 · derivative.expiration_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2014. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:43 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionPerformance Shares · Derivative | 31,546 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007232 · doc4.xml · derivative · entry 17 DANIELS BRIAN · CIK 0001428698 · SVP Global Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 31,546 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2013. F1 · shares: Represents distribution of performance shares earned under the 2010-2012 Long-Term Performance Award. F10 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2013. F10 · derivative.expiration_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2013. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:43 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherPerformance Shares · Derivative | 1,208.7713 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007232 · doc4.xml · derivative · entry 16 DANIELS BRIAN · CIK 0001428698 · SVP Global Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,546 Underlying: Common Stock, $0.10 par value · 1,208.7713 shares Expires not disclosed F12 · derivative.exercise_price: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2013. F13 · shares: Represents dividend equivalents earned under the 2010-2012 Long-Term Performance Award. F12 · derivative.exercise_date: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2013. F12 · derivative.expiration_date: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2013. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:43 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantPerformance Shares · Derivative | 9,168 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007232 · doc4.xml · derivative · entry 15 DANIELS BRIAN · CIK 0001428698 · SVP Global Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,337.2287 Underlying: Common Stock, $0.10 par value · 9,168 shares Expires not disclosed F10 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2013. F11 · shares: Represents performance shares earned under the 2010-2012 Long-Term Performance Award. F10 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2013. F10 · derivative.expiration_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2013. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.